These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32153795)

  • 1. Serum uric acid is associated with damage in patients with systemic lupus erythematosus.
    Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cardenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
    Lupus Sci Med; 2020; 7(1):e000366. PubMed ID: 32153795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients.
    Reátegui-Sokolova C; Ugarte-Gil MF; Gamboa-Cárdenas RV; Zevallos F; Cucho-Venegas JM; Alfaro-Lozano JL; Medina M; Rodriguez-Bellido Z; Pastor-Asurza CA; Alarcón GS; Perich-Campos RA
    Clin Rheumatol; 2017 Apr; 36(4):845-852. PubMed ID: 28101832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.
    Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cárdenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Zeña-Huancas PA; Pastor-Asurza CA; Perich-Campos RA; Rodríguez-Bellido ZJ; Alarcón GS; Ugarte-Gil MF
    Lupus; 2020 Oct; 29(12):1644-1649. PubMed ID: 32741305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.
    Elera-Fitzcarrald C; Reatégui-Sokolova C; Gamboa-Cárdenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano JL; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos R; Alarcón GS; Ugarte-Gil MF
    Lupus; 2022 Jan; 31(1):105-109. PubMed ID: 34989640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
    Urowitz MB; Gladman DD; Ibañez D; Su J; Mursleen S; Sayani A; Ross Terres JA; Iczkovitz S
    J Rheumatol; 2021 Jan; 48(1):67-73. PubMed ID: 32238510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort.
    Zeña-Huancas PA; Iparraguirre-López H; Gamboa-Cárdenas RV; Reátegui-Sokolova C; Zevallos-Miranda F; Medina-Chinchon M; Pimentel-Quiroz VR; Elera-Fitzcarrald C; Sarmiento-Velasquez O; Cucho-Venegas JM; Alfaro-Lozano JL; Rodríguez-Bellido ZJ; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
    Clin Rheumatol; 2019 Apr; 38(4):1139-1146. PubMed ID: 30539353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
    Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment pathways in an inception lupus cohort over the first three years.
    Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
    Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
    Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
    Front Immunol; 2018; 9():1250. PubMed ID: 29930551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients-a multicenter retrospective cohort.
    Medhat BM; Behiry ME; Sobhy N; Farag Y; Marzouk H; Mostafa N; Khalifa I; Elkhalifa M; Eissa BM; Hassan EHE
    Clin Rheumatol; 2020 Feb; 39(2):435-442. PubMed ID: 31758421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum uric acid as a sensitive concordant marker with lupus nephritis and new onset of renal damage: a prospective cohort study.
    Elnady B; Almalki A; Abdel-Fattah MM; Desouky DE; Attar M
    Clin Rheumatol; 2021 May; 40(5):1827-1834. PubMed ID: 33094396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients.
    Ugarte-Gil MF; Sánchez-Zúñiga C; Gamboa-Cardenas RV; Aliaga-Zamudio M; Zevallos F; Mosqueira-Riveros A; Medina-Chinchón M; Tineo-Pozo G; Elera-Fitzcarrald C; Pimentel-Quiroz V; Sarmiento-Velasquez O; Reátegui-Sokolova C; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza C; Alarcón GS; Perich-Campos R
    Clin Exp Rheumatol; 2018; 36(6):1008-1013. PubMed ID: 29745892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease evolution in late-onset and early-onset systemic lupus erythematosus.
    Aljohani R; Gladman DD; Su J; Urowitz MB
    Lupus; 2017 Oct; 26(11):1190-1196. PubMed ID: 28420066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
    Legge A; Kirkland S; Rockwood K; Andreou P; Bae SC; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
    Arthritis Rheumatol; 2020 Apr; 72(4):658-666. PubMed ID: 31631584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
    Barber MRW; Hanly JG; Su L; Urowitz MB; St Pierre Y; Romero-Diaz J; Gordon C; Bae SC; Bernatsky S; Wallace DJ; Merrill JT; Isenberg DA; Rahman A; Ginzler EM; Petri M; Bruce IN; Dooley MA; Fortin PR; Gladman DD; Sanchez-Guerrero J; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Farewell V; Stoll T; Buyon J; Clarke AE
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1800-1808. PubMed ID: 31609532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.